These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18336617)

  • 1. The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer.
    Ramsey S; Aitchison M; Graham J; McMillan DC
    BJU Int; 2008 Jul; 102(1):125-9. PubMed ID: 18336617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer.
    Ramsey S; Lamb GW; Aitchison M; Graham J; McMillan DC
    Cancer; 2007 Jan; 109(2):205-12. PubMed ID: 17149754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer.
    Ramsey S; Lamb GW; Aitchison M; McMillan DC
    Br J Cancer; 2006 Oct; 95(8):1076-80. PubMed ID: 17003778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer.
    Lamb GW; McArdle PA; Ramsey S; McNichol AM; Edwards J; Aitchison M; McMillan DC
    BJU Int; 2008 Sep; 102(6):756-61. PubMed ID: 18384626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer.
    Ramsey S; Lamb GW; Aitchison M; McMillan DC
    BJU Int; 2008 Apr; 101(8):959-63. PubMed ID: 18190639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
    Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
    Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
    J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of IL-2 immunotherapy in metastatic renal cell carcinoma in relation to the psychic profile as evaluated using the Rorschach test.
    Messina G; Lissoni P; Bartolacelli E; Fumagalli L; Brivio F; Colombo E; Gardani GS
    Anticancer Res; 2007; 27(4C):2985-8. PubMed ID: 17695482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
    Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
    J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.
    Royal RE; Steinberg SM; Krouse RS; Heywood G; White DE; Hwu P; Marincola FM; Parkinson DR; Schwartzentruber DJ; Topalian SL; Yang JC; Rosenberg SA
    Cancer J Sci Am; 1996; 2(2):91-8. PubMed ID: 9166506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for renal cell cancer.
    Yang JC; Childs R
    J Clin Oncol; 2006 Dec; 24(35):5576-83. PubMed ID: 17158543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma.
    Böhm M; Ittenson A; Klatte T; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
    Folia Biol (Praha); 2003; 49(2):63-8. PubMed ID: 12779014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
    Lissoni P; Mengo S; Mandalà M; Mauri E; Brivio F; Rovelli F; Confalonieri G; Longarini R; Bonfante A; Folli D; Meregalli S; Barni S; Tancini G; Giani L
    J Biol Regul Homeost Agents; 1998; 12(1-2):38-41. PubMed ID: 9677534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma.
    Donskov F; von der Maase H
    J Clin Oncol; 2006 May; 24(13):1997-2005. PubMed ID: 16648500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
    Galanis E; Burch PA; Richardson RL; Lewis B; Pitot HC; Frytak S; Spier C; Akporiaye ET; Peethambaram PP; Kaur JS; Okuno SH; Unni KK; Rubin J
    Cancer; 2004 Dec; 101(11):2557-66. PubMed ID: 15517589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
    Thompson JA; Figlin RA; Sifri-Steele C; Berenson RJ; Frohlich MW
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3562-70. PubMed ID: 14506142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory mediators and immune function are altered in home parenteral nutrition patients.
    Hise ME; Compher C; Harlan L; Kohlmeier JE; Benedict SH; Gajewski B; Brown JC
    Nutrition; 2006 Feb; 22(2):97-103. PubMed ID: 16459221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic factors for predicting the success of immunotherapy in metastatic renal cell carcinoma].
    Schmitz-Dräger BJ; Jankevicius F; Otto T
    Urologe A; 1995 May; 34(3):195-9. PubMed ID: 7610511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study.
    Litwin MS; Fine JT; Dorey F; Figlin RA; Belldegrun AS
    J Urol; 1997 May; 157(5):1608-12. PubMed ID: 9112487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.